Kentucky pharmacists' opinions of the potential reclassification of pseudoephedrine as a legend drug

Kathleen E. Monson, Patricia R. Freeman, Amie J. Goodin, Jeffery Talbert, Karen Blumenschein

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Objectives: To collect and analyze Kentucky pharmacists' opinions of the effectiveness of current methamphetamine precursor controls, to analyze proposed legislation to make pseudoephedrine (PSE) a legend drug, and to analyze the potential impact of such legislation on pharmacy practice and patients. Design: Descriptive, nonexperimental survey study. Setting: Kentucky; June through October 2012. Participants: 431 Kentucky community pharmacists. Intervention: Mailed survey. Main outcome measures: Perceived efficacy of current methamphetamine precursor controls, anticipated impact on individual pharmacy practices and patients of proposed legislation to make PSE available by prescription only, and current opinions about the proposed legislation. Results: Analysis of 431 community pharmacists showed that approximately 77% believed proposed legislation to make PSE available by prescription only would be effective in reducing methamphetamine abuse and methamphetamine-related laboratory incidents, with 56.2% indicating support for the proposed legislation. Pharmacists practicing in chain pharmacies were 2.9 times more likely to support the legislation than pharmacists practicing in independent pharmacies. Additional factors influencing pharmacist support included Kentucky region of practice, anticipated impact on time spent on PSE activities, pharmacy profit, methamphetamine abuse, and methamphetamine-related laboratory incidents. Pharmacists practicing in regions of Kentucky associated with higher methamphetamine abuse appear to more strongly support the proposed legislation. Conclusion: Pharmacists are at the frontline of PSE distribution. Gaining a better understanding of issues surrounding the distribution of PSE will enhance the likelihood that future legislation may be crafted to reduce methamphetamine production, laboratory incidents, and abuse while minimizing inconvenience and cost.

Original languageEnglish
Pages (from-to)397-405
Number of pages9
JournalJournal of the American Pharmacists Association
Issue number4
StatePublished - 2014

Bibliographical note

Funding Information:
Consumer-focused studies funded by the Asthma and Allergy Foundation of America and the Consumer Healthcare Products Association, both of which largely oppose the proposed prescription-only PSE legislation, have shown that a majority of consumers oppose such legislation. 6 , 7


  • Community pharmacy
  • Methamphetamine
  • Over-the-counter
  • Precursor regulation
  • Prescription
  • Pseudoephedrine

ASJC Scopus subject areas

  • Pharmacology (nursing)
  • Pharmacy
  • Pharmacology


Dive into the research topics of 'Kentucky pharmacists' opinions of the potential reclassification of pseudoephedrine as a legend drug'. Together they form a unique fingerprint.

Cite this